Valuation: Cogstate Limited

Market Cap 440M 311M 269M 251M 230M 433M 29.58B 2.95B 1.16B 14.82B 1.17B 1.14B 49.01B P/E 2026 *
26.3x
P/E 2027 * 19.4x
Enterprise Value 383M 270M 234M 218M 200M 377M 25.73B 2.56B 1.01B 12.9B 1.02B 993M 42.64B EV / Sales 2026 *
4.4x
EV / Sales 2027 * 3.6x
Free-Float
54.18%
Yield 2026 *
1.26%
Yield 2027 * 1.58%

Last Transcript: Cogstate Limited

1 day+0.01%
1 week-8.57%
Current month-8.57%
1 month-14.43%
3 months-9.09%
6 months+5.97%
Current year+0.01%
1 week 1.6
Extreme 1.6
1.6
1 month 1.6
Extreme 1.6
1.99
Current year 1.26
Extreme 1.26
1.99
1 year 1
Extreme 1
2.1
3 years 0.55
Extreme 0.553
2.1
5 years 0.55
Extreme 0.553
2.1
10 years 0.14
Extreme 0.14
2.1
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 1999-12-16
Chief Executive Officer - 2005-11-30
Director of Finance/CFO - 2021-01-31
Director TitleAgeSince
Director/Board Member - 2011-02-28
Chairman 67 2009-11-02
Director/Board Member - 2017-01-19
Change 5-day change 1-year change 3-year change Capi.($)
+0.01%-8.57% - - 314M
+0.99%+1.78%+4.07%+16.73% 48.7B
+3.71%+9.40%+486.98%+592.14% 42.05B
+2.70%+1.57%+33.39%+8.85% 38.26B
+5.60%+10.21%+16.76%+85.72% 37.5B
+2.21%+6.75%+21.31%+53.37% 31.44B
+2.23%+4.71% - - 16.47B
+0.97%+2.35%+37.75%+126.84% 16.33B
-0.11%+2.41%+6.24%+18.87% 13.98B
+0.75%+15.04%+78.59%+30.30% 12.68B
Average +1.91%+5.63%+85.64%+116.60% 28.6B
Weighted average by Cap. +2.51%+5.04%+103.57%+139.73%

Financials

2026 *2027 *
Net sales 86.95M 61.41M 53.12M 49.6M 45.5M 85.59M 5.84B 582M 228M 2.93B 231M 226M 9.68B 102M 72.22M 62.47M 58.34M 53.52M 101M 6.87B 684M 269M 3.45B 271M 265M 11.39B
Net income 16.9M 11.94M 10.32M 9.64M 8.84M 16.63M 1.14B 113M 44.4M 569M 44.82M 43.84M 1.88B 22.92M 16.19M 14M 13.08M 12M 22.56M 1.54B 153M 60.22M 772M 60.8M 59.46M 2.55B
Net Debt -57.17M -40.38M -34.93M -32.62M -29.92M -56.28M -3.84B -383M -150M -1.93B -152M -148M -6.37B -72.31M -51.07M -44.18M -41.25M -37.84M -71.18M -4.86B -484M -190M -2.44B -192M -188M -8.05B
Logo Cogstate Limited
Cogstate Limited is a neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Its principal activities are the creation, validation, and commercialization of digital brain health assessments; and design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its segments include Clinical Trials, Healthcare, and Administration. In the Clinical Trials segment, the technology and associated services are used to quantify the effect of disease and of drugs, devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical, and biotechnology companies. In the Healthcare segment, the technology and associated services are being developed as a tool for primary care physicians and/or hospitals to assess cognitive decline.
Employees
160
Date Price Change Volume
26-08-05 US$1.600 +0.01% 175
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.590AUD
Average target price
3.540AUD
Spread / Average Target
+36.68%

Quarterly revenue - Rate of surprise